ProtheraCytes is under clinical development by CellProthera and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II drugs for Myocardial Infarction have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ProtheraCytes’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ProtheraCytes overview
ProtheraCytes (Autologous CD34 stem cell therapy) is under development to repair myocardial tissue after acute myocardial infarct (AMI), ischemic stroke and refractory angina. It is administered intraventricular and intramyocardially. The therapy is a cell graft containing autologous adult stem cells (ASC) sampled directly from the patient. The therapeutic candidate is administered by injection. It is derived form AMI patient’s blood sample and treated with G-CSF (Granulocyte colony-stimulating factor), these CD34+ cells are mobilized by Granulocyte colony-stimulating factor (G-CSF). It is developed by using helix transendocardial delivery system.
CellProthera overview
CellProthera is a biotechnology company that carries out the development of cell therapy solutions. The company focuses on the potential of CD34+ stem cells for the treatment of acute ischemic stroke and refractory angina. Its major product ProtheraCytes, is a preparation of stem cells with the potential to regenerate various damaged tissues, including cardiac tissue. CellProthera’s proprietary technology platform comprises an automated expansion device called StemXpand and its disposable kit StemPack. The company’s products treat cerebrovascular diseases and heart conditions. CellProthera markets its products under the brands StemXpand, StemPack, ProtheraCytes and StemFeed. CellProthera operates through an office and research and development facility in France. CellProthera is headquartered in Mulhouse, France.
For a complete picture of ProtheraCytes’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
